We work Hard to get you posted with latest updates

http://We%20work%20Hard%20to%20get%20you%20posted%20with%20latest%20updates

Spend time learning about the different aspects of that topic from experts in the field.

Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy

Unwrap our new Directory

http://Unwrap%20our%20new%20Directory

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

Scancell

Advertisement

cGxPJobs Banner

FDA Clears Scancell IND for Phase 3 iSCIB1+ Melanoma Trial

Cambridge, United Kingdom, January 26, 2026 — Scancell Holdings plc announced on January 26, 2026, that the U.S. Food...

By cGxPwire Editor
January 26, 2026

Read More

Advertisement

cGxPJobs

Recent Posts

01

.Clinical

Nuvation Bio Strengthens Oncology Pipeline with IBTROZI and Safusidenib Advances
April 22, 2026
02

.Clinical

Akeso Cadonilimab Combo Shows Strong Survival in Pancreatic Cancer
April 22, 2026
03

Bio-Pharma

Insilico Medicine Launches Longevity Board for AI Drug Discovery
April 22, 2026
04

.Clinical

Monopar ALXN1840 Phase 3 Data Improves Wilson Disease Outcomes
April 22, 2026
05

Bio-Pharma

Biocon Gains Health Canada Nod for Denosumab Biosimilars
April 22, 2026

Advertisement

Copyright © 2026 cGxP.wire | Made by 3styler

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

Start typing and press Enter to search

Loading Comments...

Write a Comment...

Email (Required)

Name (Required)

Website